SUMMARY -Th e aim of the study was to evaluate the possible association between Apo E polymorphisms and age at seizure onset in patients with non-lesional temporal lobe epilepsy. Eighty patients with non-lesional temporal lobe epilepsy with or without bilateral tonic-clonic propagation were analyzed. Age at seizure onset was defi ned as age at the fi rst unequivocal seizure (excluding febrile convulsions). ApoE alleles were determined by a procedure where genome DNA was amplifi ed by chain reaction along with polymerase, using the LightCycler kit (Roche) for ApoE mutations on codons 112 and 158. Th ere was a statistically signifi cant diff erence between the groups of patients with ApoE ε2/3 and ε3/4 genotypes (p=0.03), but not between patients with ApoE ε2/3 and ε3/3, and those with ApoE ε3/4 and ε3/3. In conclusion, the results of our study suggested positive association of a specifi c ApoE genotype and onset of non-lesional temporal lobe epilepsy.
Introduction
Apolipoprotein E (ApoE) as the main carrier of lipids in the brain is thought to be especially important for repair mechanisms in the central nervous system (CNS) [1] [2] [3] . After neuronal tissue damage, the synthesis of the ApoE protein is up-regulated in the reactive astrocytes 4, 5 . However, ApoE isoforms vary in their neuroprotective properties 6, 7 . ApoE defi ciency has been shown to adversely aff ect outcome after transient cerebral ischemia and head trauma. Since oxidative stress contributes to these injuries, the ability of ApoE to reduce irreversible oxidative damage was studied 8, 9 . Th e ApoE gene is a confi rmed genetic risk factor that infl uences both the risk and age at onset of Alzheimer's disease and Parkinson's disease 10 . ApoE is also associated with age at onset in some other degenerative neurological diseases [11] [12] [13] [14] . With the increasing evidence for the role of ApoE in repair mechanisms in the brain 3 , ApoE polymorphisms and their link to temporal lobe epilepsy (TLE) has attracted ever more attention 15, 16 . It is therefore possible that some developmental or childhood brain injury has occurred in a person with ApoE ε4, and there may be a failure to repair the damage, resulting in an epileptogenic lesion.
Based on pathological data derived from temporal lobe specimens of patients with TLE, ApoE may well be accepted as one of the susceptibility genes, a marker to identify people at risk of early or delayed onset of developing epilepsy. ApoE ε4 genotype is associated with an earlier onset of chronic TLE 17 , but some other studies were not able to fi nd a link between TLE, onset of disease and ApoE polymorphism [18] [19] [20] . Th e aim of this study was to evaluate the association between ApoE polymorphism and age at onset in patients with non-lesional TLE.
Patients and Methods

Patients
In this study, 80 patients with non-lesional TLE with or without bilateral tonic-clonic propagation were analyzed during a six-year period (2006) (2007) (2008) (2009) (2010) (2011) (2012) . Th e study was conducted at Zagreb University Hospital Center and Dubrava University Hospital in Zagreb. Diagnosis of TLE was based on clinical history, seizure semiology and interictal electroencephalographic (EEG) monitoring. Age at seizure onset was the age of the subject at the fi rst unequivocal seizure (excluding febrile convulsions) as determined retrospectively after having collected all available information. TLE was classifi ed as non-lesional if no epileptogenic foreign-tissue lesion was detected on brain magnetic resonance imaging (MRI; epilepsy protocol, power 1.5T). Demographic and basic characteristics of study groups are shown in Table 1 . Th e inclusion criteria were adult subject diagnosed with non-lesional TLE with or without secondarily generalized seizures lasting for at least three years. Subjects with a history of CNS infection, head trauma, brain tumor, cerebrocentrifuged, the cells were separated from the liquid blood phase, and both fractions were deeply frozen. Purifi cation of DNA from blood was done with a commercial BioSprint 15 DNA Blood Kit (Qiagen, Germantown, USA). ApoE alleles were determined by a procedure where genome DNA was amplifi ed by chain reaction along with polymerase, using the LightCycler kit (Roche, Mannheim, Germany) for ApoE mutations on codons 112 and 158.
Statistics
Microsoft SPSS statistical package for Windows, version 10.0 was used. Results were expressed as mean value and standard deviation (SD). Diff erences between the groups were tested by analysis of variance (ANOVA) and post-hoc Tukey test. Th e p-value of <0.05 was considered statistically signifi cant.
Th e study was approved by the local ethics committee, and all patients signed the informed consent form to take part in the study.
Results
Distribution of the alleles in patients with non-lesional TLE was as follows: ε2/3 in seven (8.75%) pa- 
Genotyping
Blood samples for determination of ApoE genotype were obtained from all patients. Th e sample was Th ere was a statistically signifi cant diff erence between the groups of patients with ApoE ε2/3 and ε3/4 genotype (p=0.03), but not between patients with ApoE ε2/3 and ε3/3, and those with Apo E ε3/4 and ε3/3. Diff erences between the groups were tested by analysis of variance (ANOVA) and post-hoc Tukey test. Th e p-value of <0.05 was considered statistically signifi cant.
Fig. 1. Age at onset of temporal lobe seizure and ApoE genotype polymorphism.
tients, ε3/3 in 57 (71.25%) patients and ε3/4 in 16 (20.00%) patients. Th ere were no patients with ApoE 2/2, 2/4, and 4/4 genotypes.
Th e average age at onset of temporal lobe seizure was 24±11 years in patients with ApoE ε2/3 genotype, 14±8 in patients with ApoE ε3/4 genotype, and 18±9 years in those with ApoE ε3/3 genotype. Th ere was a statistically signifi cant diff erence between the groups of patients with ApoE ε2/3 and ε3/4 genotypes (p=0.03), but not between the patients with ApoE ε2/3 and ε3/3 genotypes, and those with ApoE ε3/4 and ε3/3 genotypes (Fig. 1) .
Discussion
Study results showed that patients with non-lesional TLE and Apo E ε2/3 genotype had a statistically signifi cantly delayed onset of disease as compared to patients with ApoE ε3/4 genotype. Patients with ApoE ε3/3 genotype also had the average age at onset of disease four years later than patients with Apo E ε3/4 genotype and six years earlier than patients with ApoE ε2/3, but diff erence between these groups of patients did not reach statistical signifi cance. A small sample size might be one of the reasons for this. Th e frequency of ApoE alleles among our subjects was similar to that reported in healthy European population. Th e results may suggest an association of ApoE ε2 and recovery/plasticity of the cell membrane, but may also support the possible neuroprotective role of ApoE ε2 genotype in patients with delayed onset of disease and less protective role of ApoE ε4 genotype in patients with earlier onset of disease.
Our results are consistent with those reported from the study by Briellmann et al., where apoE ε4 allele was associated with an earlier onset of TLE 17 . Patients with e4 allele had the average age at onset of disease ten years earlier than patients without e4 allele. Moreover, as the majority of patients had an early childhood lesion, these fi ndings suggest that ApoE e4 allele may have an important eff ect on determining the length of the silent interval. In contrast to this, there was no difference in the age at onset of epilepsy in patients with focal seizures with copy of the e2, e3 or e4 allele in studies by Kilpatric et al. 18 and Blumke et al. 19 . Th e same result has been reported by Yeni et al. 20 in a group of patients suff ering from mesial temporal lobe epilepsy-hippocampal sclerosis, and by Kauff man et al. 21 .
Th e neuroprotective properties of ApoE isoforms were investigated in several experimental studies on cell cultures and on mice. ApoE ε2 and ApoE ε3, in contrast to ApoE ε4, enhance neuronal growth and increase resistance of cell cultures to oxidative stress 22 . Th e presence of recombinant human ApoE ε2 in primary mixed neuronal-glial cell cultures partially protected against oxidative injury by reducing secondary glutamate excitotoxicity 23 . Furthermore, ApoE deficient mice are more prone to oxidative tissue damage after ischemia than mice with normal ApoE production 8 . Similarly, transgenic mice with the ApoE ε3/3 genotype have a better neurological outcome and survival rate after ischemic and oxidative stress than mice with the ApoE ε4/4 genotype 9,24 . Th ese results clearly indicate a neuroprotective eff ect of Apo E by preserving the integrity of neuronal membranes, with ApoE ε/ApoE ε2 being more eff ective than Apo E ε4.
Th e neuroprotective role of ApoE polymorphism and oxidative stress caused by free radicals were also investigated in some other chronic degenerative neurological diseases. Th e epsilon 4 allele of the ApoE gene has been consistently associated with an earlier onset of Alzheimer's and Parkinson's disease 10, 25, 26 . Th e ApoE e4 allele seems to predispose carriers with multiple sclerosis to faster progression of the disease 13 . In Wilson's disease, the ApoE genotype was established as an important factor delaying the onset of neurological and hepatic symptoms 14 . Th e presence of Apo E e3/3 attenuates clinical manifestation by a mechanism that may involve the antioxidant and membranestabilizing properties of the ApoE ε3 protein, while the onset of symptoms was signifi cantly delayed in patients with the ApoE ε3/4 genotype. ApoE ε2 is protective against earlier onset of amyotrophic lateral sclerosis with an average age at onset in ApoE ε2 carriers approximately 3 years later than in non-ApoE ε2 carriers 11 . In conclusion, results of our study suggest that polymorphism of ApoE genotype might be a marker that is associated with the onset of disease in patients with non-lesional TLE.
